GlassScriptPhysician profile
Sarah Gill
NPI 1447086707
$1,003.53
in general payments reported to CMS, 2019-2025
12 companies · $699 in 2025
The $699 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $305 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.62 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $204.55 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $152.46 | 2025 | |
| Vanda Pharmaceuticals INC. | $147.20 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.58 | 2024-2025 | Caplyta |
| Lundbeck LLC | $100.17 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $66.13 | 2024 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $64.75 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $56.69 | 2024-2025 | Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $36.35 | 2024-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $34.95 | 2024-2025 | Invega Sustenna, Spravato |
| Vertex Pharmaceuticals Incorporated | $20.98 | 2025 | |
| Noven Therapeutics, LLC | $18.72 | 2024 | Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.